ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Dermatomyositis Treatment Market Research Report 2024
Published Date: July 2024
|
Report Code: QYRE-Auto-35I13296
Home | Market Reports | Health| Health Conditions
Global Dermatomyositis Treatment Market Research Report 2023
BUY CHAPTERS

Global Dermatomyositis Treatment Market Research Report 2024

Code: QYRE-Auto-35I13296
Report
July 2024
Pages:89
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Endo International, Inc.
Teva Pharmaceutical Industries Ltd
Glenmark Pharmaceuticals Ltd
Cipla Ltd
Dr. Reddy’s Laboratories Ltd.
Abbott
F Hoffmann La Roche Ltd
Pfizer Inc
Zydus Group
Lupin Ltd
Amorphex Therapeutics Holdings, Inc
Bausch Health Companies Inc.

Dermatomyositis Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Dermatomyositis Treatment Market

Dermatomyositis Treatment Market

Dermatomyositis is a rare inflammatory skin disorders that is typically characterized by muscle weakness and a severe skin rash. It is mainly caused by either viral infection of the tissues of skeletal muscle or autoimmune reaction. Symptoms may vary broadly from patient to patient. Deformities in the muscles may initiate with weakness and pain in the muscles of the thighs, the hips, the upper arms, and the trunk. The muscles may become sore, tender, and stiff and eventually express signs of degeneration.
The global Dermatomyositis Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Dermatomyositis Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dermatomyositis Treatment.

Report Scope

The Dermatomyositis Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dermatomyositis Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dermatomyositis Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Dermatomyositis Treatment Market Report

Report Metric Details
Report Name Dermatomyositis Treatment Market
CAGR 5%
Segment by Type
  • Immunosuppressants
  • Glucocorticoids
Segment by Application
  • Hospital
  • Specialty Clinic
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Cipla Inc, Dr Reddy's Laboratories Ltd, Abbott, F. Hoffmann -La Roche Ltd, Pfizer Inc, Zydus Group, Lupin, Amorphex Therapeutics Holdings, Inc, Bausch Health Companies Inc
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Dermatomyositis Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Dermatomyositis Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Dermatomyositis Treatment Market report?

Ans: The main players in the Dermatomyositis Treatment Market are Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Cipla Inc, Dr Reddy's Laboratories Ltd, Abbott, F. Hoffmann -La Roche Ltd, Pfizer Inc, Zydus Group, Lupin, Amorphex Therapeutics Holdings, Inc, Bausch Health Companies Inc

What are the Application segmentation covered in the Dermatomyositis Treatment Market report?

Ans: The Applications covered in the Dermatomyositis Treatment Market report are Hospital, Specialty Clinic, Other

What are the Type segmentation covered in the Dermatomyositis Treatment Market report?

Ans: The Types covered in the Dermatomyositis Treatment Market report are Immunosuppressants, Glucocorticoids

1 Dermatomyositis Treatment Market Overview
1.1 Product Overview and Scope of Dermatomyositis Treatment
1.2 Dermatomyositis Treatment Segment by Type
1.2.1 Global Dermatomyositis Treatment Market Value Comparison by Type (2024-2030)
1.2.2 Immunosuppressants
1.2.3 Glucocorticoids
1.3 Dermatomyositis Treatment Segment by Application
1.3.1 Global Dermatomyositis Treatment Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Other
1.4 Global Dermatomyositis Treatment Market Size Estimates and Forecasts
1.4.1 Global Dermatomyositis Treatment Revenue 2019-2030
1.4.2 Global Dermatomyositis Treatment Sales 2019-2030
1.4.3 Global Dermatomyositis Treatment Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Dermatomyositis Treatment Market Competition by Manufacturers
2.1 Global Dermatomyositis Treatment Sales Market Share by Manufacturers (2019-2024)
2.2 Global Dermatomyositis Treatment Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Dermatomyositis Treatment Average Price by Manufacturers (2019-2024)
2.4 Global Dermatomyositis Treatment Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Dermatomyositis Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Dermatomyositis Treatment, Product Type & Application
2.7 Dermatomyositis Treatment Market Competitive Situation and Trends
2.7.1 Dermatomyositis Treatment Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Dermatomyositis Treatment Players Market Share by Revenue
2.7.3 Global Dermatomyositis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Dermatomyositis Treatment Retrospective Market Scenario by Region
3.1 Global Dermatomyositis Treatment Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Dermatomyositis Treatment Global Dermatomyositis Treatment Sales by Region: 2019-2030
3.2.1 Global Dermatomyositis Treatment Sales by Region: 2019-2024
3.2.2 Global Dermatomyositis Treatment Sales by Region: 2025-2030
3.3 Global Dermatomyositis Treatment Global Dermatomyositis Treatment Revenue by Region: 2019-2030
3.3.1 Global Dermatomyositis Treatment Revenue by Region: 2019-2024
3.3.2 Global Dermatomyositis Treatment Revenue by Region: 2025-2030
3.4 North America Dermatomyositis Treatment Market Facts & Figures by Country
3.4.1 North America Dermatomyositis Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Dermatomyositis Treatment Sales by Country (2019-2030)
3.4.3 North America Dermatomyositis Treatment Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Dermatomyositis Treatment Market Facts & Figures by Country
3.5.1 Europe Dermatomyositis Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Dermatomyositis Treatment Sales by Country (2019-2030)
3.5.3 Europe Dermatomyositis Treatment Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Dermatomyositis Treatment Market Facts & Figures by Country
3.6.1 Asia Pacific Dermatomyositis Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Dermatomyositis Treatment Sales by Country (2019-2030)
3.6.3 Asia Pacific Dermatomyositis Treatment Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Dermatomyositis Treatment Market Facts & Figures by Country
3.7.1 Latin America Dermatomyositis Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Dermatomyositis Treatment Sales by Country (2019-2030)
3.7.3 Latin America Dermatomyositis Treatment Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Dermatomyositis Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Dermatomyositis Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Dermatomyositis Treatment Sales by Country (2019-2030)
3.8.3 Middle East and Africa Dermatomyositis Treatment Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Dermatomyositis Treatment Sales by Type (2019-2030)
4.1.1 Global Dermatomyositis Treatment Sales by Type (2019-2024)
4.1.2 Global Dermatomyositis Treatment Sales by Type (2025-2030)
4.1.3 Global Dermatomyositis Treatment Sales Market Share by Type (2019-2030)
4.2 Global Dermatomyositis Treatment Revenue by Type (2019-2030)
4.2.1 Global Dermatomyositis Treatment Revenue by Type (2019-2024)
4.2.2 Global Dermatomyositis Treatment Revenue by Type (2025-2030)
4.2.3 Global Dermatomyositis Treatment Revenue Market Share by Type (2019-2030)
4.3 Global Dermatomyositis Treatment Price by Type (2019-2030)
5 Segment by Application
5.1 Global Dermatomyositis Treatment Sales by Application (2019-2030)
5.1.1 Global Dermatomyositis Treatment Sales by Application (2019-2024)
5.1.2 Global Dermatomyositis Treatment Sales by Application (2025-2030)
5.1.3 Global Dermatomyositis Treatment Sales Market Share by Application (2019-2030)
5.2 Global Dermatomyositis Treatment Revenue by Application (2019-2030)
5.2.1 Global Dermatomyositis Treatment Revenue by Application (2019-2024)
5.2.2 Global Dermatomyositis Treatment Revenue by Application (2025-2030)
5.2.3 Global Dermatomyositis Treatment Revenue Market Share by Application (2019-2030)
5.3 Global Dermatomyositis Treatment Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis AG
6.1.1 Novartis AG Corporation Information
6.1.2 Novartis AG Description and Business Overview
6.1.3 Novartis AG Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis AG Dermatomyositis Treatment Product Portfolio
6.1.5 Novartis AG Recent Developments/Updates
6.2 Endo International Inc
6.2.1 Endo International Inc Corporation Information
6.2.2 Endo International Inc Description and Business Overview
6.2.3 Endo International Inc Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Endo International Inc Dermatomyositis Treatment Product Portfolio
6.2.5 Endo International Inc Recent Developments/Updates
6.3 Teva Pharmaceutical Industries Ltd
6.3.1 Teva Pharmaceutical Industries Ltd Corporation Information
6.3.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
6.3.3 Teva Pharmaceutical Industries Ltd Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Teva Pharmaceutical Industries Ltd Dermatomyositis Treatment Product Portfolio
6.3.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
6.4 Glenmark Pharmaceuticals Ltd
6.4.1 Glenmark Pharmaceuticals Ltd Corporation Information
6.4.2 Glenmark Pharmaceuticals Ltd Description and Business Overview
6.4.3 Glenmark Pharmaceuticals Ltd Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Glenmark Pharmaceuticals Ltd Dermatomyositis Treatment Product Portfolio
6.4.5 Glenmark Pharmaceuticals Ltd Recent Developments/Updates
6.5 Cipla Inc
6.5.1 Cipla Inc Corporation Information
6.5.2 Cipla Inc Description and Business Overview
6.5.3 Cipla Inc Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Cipla Inc Dermatomyositis Treatment Product Portfolio
6.5.5 Cipla Inc Recent Developments/Updates
6.6 Dr Reddy's Laboratories Ltd
6.6.1 Dr Reddy's Laboratories Ltd Corporation Information
6.6.2 Dr Reddy's Laboratories Ltd Description and Business Overview
6.6.3 Dr Reddy's Laboratories Ltd Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Dr Reddy's Laboratories Ltd Dermatomyositis Treatment Product Portfolio
6.6.5 Dr Reddy's Laboratories Ltd Recent Developments/Updates
6.7 Abbott
6.6.1 Abbott Corporation Information
6.6.2 Abbott Description and Business Overview
6.6.3 Abbott Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Abbott Dermatomyositis Treatment Product Portfolio
6.7.5 Abbott Recent Developments/Updates
6.8 F. Hoffmann -La Roche Ltd
6.8.1 F. Hoffmann -La Roche Ltd Corporation Information
6.8.2 F. Hoffmann -La Roche Ltd Description and Business Overview
6.8.3 F. Hoffmann -La Roche Ltd Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.8.4 F. Hoffmann -La Roche Ltd Dermatomyositis Treatment Product Portfolio
6.8.5 F. Hoffmann -La Roche Ltd Recent Developments/Updates
6.9 Pfizer Inc
6.9.1 Pfizer Inc Corporation Information
6.9.2 Pfizer Inc Description and Business Overview
6.9.3 Pfizer Inc Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Pfizer Inc Dermatomyositis Treatment Product Portfolio
6.9.5 Pfizer Inc Recent Developments/Updates
6.10 Zydus Group
6.10.1 Zydus Group Corporation Information
6.10.2 Zydus Group Description and Business Overview
6.10.3 Zydus Group Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Zydus Group Dermatomyositis Treatment Product Portfolio
6.10.5 Zydus Group Recent Developments/Updates
6.11 Lupin
6.11.1 Lupin Corporation Information
6.11.2 Lupin Dermatomyositis Treatment Description and Business Overview
6.11.3 Lupin Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Lupin Dermatomyositis Treatment Product Portfolio
6.11.5 Lupin Recent Developments/Updates
6.12 Amorphex Therapeutics Holdings, Inc
6.12.1 Amorphex Therapeutics Holdings, Inc Corporation Information
6.12.2 Amorphex Therapeutics Holdings, Inc Dermatomyositis Treatment Description and Business Overview
6.12.3 Amorphex Therapeutics Holdings, Inc Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Amorphex Therapeutics Holdings, Inc Dermatomyositis Treatment Product Portfolio
6.12.5 Amorphex Therapeutics Holdings, Inc Recent Developments/Updates
6.13 Bausch Health Companies Inc
6.13.1 Bausch Health Companies Inc Corporation Information
6.13.2 Bausch Health Companies Inc Dermatomyositis Treatment Description and Business Overview
6.13.3 Bausch Health Companies Inc Dermatomyositis Treatment Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Bausch Health Companies Inc Dermatomyositis Treatment Product Portfolio
6.13.5 Bausch Health Companies Inc Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Dermatomyositis Treatment Industry Chain Analysis
7.2 Dermatomyositis Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Dermatomyositis Treatment Production Mode & Process
7.4 Dermatomyositis Treatment Sales and Marketing
7.4.1 Dermatomyositis Treatment Sales Channels
7.4.2 Dermatomyositis Treatment Distributors
7.5 Dermatomyositis Treatment Customers
8 Dermatomyositis Treatment Market Dynamics
8.1 Dermatomyositis Treatment Industry Trends
8.2 Dermatomyositis Treatment Market Drivers
8.3 Dermatomyositis Treatment Market Challenges
8.4 Dermatomyositis Treatment Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novartis
Endo International, Inc.
Teva Pharmaceutical Industries Ltd
Glenmark Pharmaceuticals Ltd
Cipla Ltd
Dr. Reddy’s Laboratories Ltd.
Abbott
F Hoffmann La Roche Ltd
Pfizer Inc
Zydus Group
Lupin Ltd
Amorphex Therapeutics Holdings, Inc
Bausch Health Companies Inc.
List of Tables
    Table 1. Global Dermatomyositis Treatment Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Dermatomyositis Treatment Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Dermatomyositis Treatment Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Dermatomyositis Treatment Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Dermatomyositis Treatment Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Dermatomyositis Treatment Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Dermatomyositis Treatment Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Dermatomyositis Treatment Average Price (US$/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Dermatomyositis Treatment, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Dermatomyositis Treatment, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Dermatomyositis Treatment, Product Type & Application
    Table 12. Global Key Manufacturers of Dermatomyositis Treatment, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Dermatomyositis Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dermatomyositis Treatment as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Dermatomyositis Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Dermatomyositis Treatment Sales by Region (2019-2024) & (K Units)
    Table 18. Global Dermatomyositis Treatment Sales Market Share by Region (2019-2024)
    Table 19. Global Dermatomyositis Treatment Sales by Region (2025-2030) & (K Units)
    Table 20. Global Dermatomyositis Treatment Sales Market Share by Region (2025-2030)
    Table 21. Global Dermatomyositis Treatment Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Dermatomyositis Treatment Revenue Market Share by Region (2019-2024)
    Table 23. Global Dermatomyositis Treatment Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Dermatomyositis Treatment Revenue Market Share by Region (2025-2030)
    Table 25. North America Dermatomyositis Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Dermatomyositis Treatment Sales by Country (2019-2024) & (K Units)
    Table 27. North America Dermatomyositis Treatment Sales by Country (2025-2030) & (K Units)
    Table 28. North America Dermatomyositis Treatment Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Dermatomyositis Treatment Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Dermatomyositis Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Dermatomyositis Treatment Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Dermatomyositis Treatment Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Dermatomyositis Treatment Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Dermatomyositis Treatment Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Dermatomyositis Treatment Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Dermatomyositis Treatment Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Dermatomyositis Treatment Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Dermatomyositis Treatment Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Dermatomyositis Treatment Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Dermatomyositis Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Dermatomyositis Treatment Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Dermatomyositis Treatment Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Dermatomyositis Treatment Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Dermatomyositis Treatment Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Dermatomyositis Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Dermatomyositis Treatment Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Dermatomyositis Treatment Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Dermatomyositis Treatment Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Dermatomyositis Treatment Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Dermatomyositis Treatment Sales (K Units) by Type (2019-2024)
    Table 51. Global Dermatomyositis Treatment Sales (K Units) by Type (2025-2030)
    Table 52. Global Dermatomyositis Treatment Sales Market Share by Type (2019-2024)
    Table 53. Global Dermatomyositis Treatment Sales Market Share by Type (2025-2030)
    Table 54. Global Dermatomyositis Treatment Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Dermatomyositis Treatment Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Dermatomyositis Treatment Revenue Market Share by Type (2019-2024)
    Table 57. Global Dermatomyositis Treatment Revenue Market Share by Type (2025-2030)
    Table 58. Global Dermatomyositis Treatment Price (US$/Unit) by Type (2019-2024)
    Table 59. Global Dermatomyositis Treatment Price (US$/Unit) by Type (2025-2030)
    Table 60. Global Dermatomyositis Treatment Sales (K Units) by Application (2019-2024)
    Table 61. Global Dermatomyositis Treatment Sales (K Units) by Application (2025-2030)
    Table 62. Global Dermatomyositis Treatment Sales Market Share by Application (2019-2024)
    Table 63. Global Dermatomyositis Treatment Sales Market Share by Application (2025-2030)
    Table 64. Global Dermatomyositis Treatment Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Dermatomyositis Treatment Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Dermatomyositis Treatment Revenue Market Share by Application (2019-2024)
    Table 67. Global Dermatomyositis Treatment Revenue Market Share by Application (2025-2030)
    Table 68. Global Dermatomyositis Treatment Price (US$/Unit) by Application (2019-2024)
    Table 69. Global Dermatomyositis Treatment Price (US$/Unit) by Application (2025-2030)
    Table 70. Novartis AG Corporation Information
    Table 71. Novartis AG Description and Business Overview
    Table 72. Novartis AG Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 73. Novartis AG Dermatomyositis Treatment Product
    Table 74. Novartis AG Recent Developments/Updates
    Table 75. Endo International Inc Corporation Information
    Table 76. Endo International Inc Description and Business Overview
    Table 77. Endo International Inc Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 78. Endo International Inc Dermatomyositis Treatment Product
    Table 79. Endo International Inc Recent Developments/Updates
    Table 80. Teva Pharmaceutical Industries Ltd Corporation Information
    Table 81. Teva Pharmaceutical Industries Ltd Description and Business Overview
    Table 82. Teva Pharmaceutical Industries Ltd Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 83. Teva Pharmaceutical Industries Ltd Dermatomyositis Treatment Product
    Table 84. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
    Table 85. Glenmark Pharmaceuticals Ltd Corporation Information
    Table 86. Glenmark Pharmaceuticals Ltd Description and Business Overview
    Table 87. Glenmark Pharmaceuticals Ltd Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 88. Glenmark Pharmaceuticals Ltd Dermatomyositis Treatment Product
    Table 89. Glenmark Pharmaceuticals Ltd Recent Developments/Updates
    Table 90. Cipla Inc Corporation Information
    Table 91. Cipla Inc Description and Business Overview
    Table 92. Cipla Inc Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 93. Cipla Inc Dermatomyositis Treatment Product
    Table 94. Cipla Inc Recent Developments/Updates
    Table 95. Dr Reddy's Laboratories Ltd Corporation Information
    Table 96. Dr Reddy's Laboratories Ltd Description and Business Overview
    Table 97. Dr Reddy's Laboratories Ltd Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 98. Dr Reddy's Laboratories Ltd Dermatomyositis Treatment Product
    Table 99. Dr Reddy's Laboratories Ltd Recent Developments/Updates
    Table 100. Abbott Corporation Information
    Table 101. Abbott Description and Business Overview
    Table 102. Abbott Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 103. Abbott Dermatomyositis Treatment Product
    Table 104. Abbott Recent Developments/Updates
    Table 105. F. Hoffmann -La Roche Ltd Corporation Information
    Table 106. F. Hoffmann -La Roche Ltd Description and Business Overview
    Table 107. F. Hoffmann -La Roche Ltd Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 108. F. Hoffmann -La Roche Ltd Dermatomyositis Treatment Product
    Table 109. F. Hoffmann -La Roche Ltd Recent Developments/Updates
    Table 110. Pfizer Inc Corporation Information
    Table 111. Pfizer Inc Description and Business Overview
    Table 112. Pfizer Inc Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 113. Pfizer Inc Dermatomyositis Treatment Product
    Table 114. Pfizer Inc Recent Developments/Updates
    Table 115. Zydus Group Corporation Information
    Table 116. Zydus Group Description and Business Overview
    Table 117. Zydus Group Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 118. Zydus Group Dermatomyositis Treatment Product
    Table 119. Zydus Group Recent Developments/Updates
    Table 120. Lupin Corporation Information
    Table 121. Lupin Description and Business Overview
    Table 122. Lupin Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 123. Lupin Dermatomyositis Treatment Product
    Table 124. Lupin Recent Developments/Updates
    Table 125. Amorphex Therapeutics Holdings, Inc Corporation Information
    Table 126. Amorphex Therapeutics Holdings, Inc Description and Business Overview
    Table 127. Amorphex Therapeutics Holdings, Inc Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 128. Amorphex Therapeutics Holdings, Inc Dermatomyositis Treatment Product
    Table 129. Amorphex Therapeutics Holdings, Inc Recent Developments/Updates
    Table 130. Bausch Health Companies Inc Corporation Information
    Table 131. Bausch Health Companies Inc Description and Business Overview
    Table 132. Bausch Health Companies Inc Dermatomyositis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 133. Bausch Health Companies Inc Dermatomyositis Treatment Product
    Table 134. Bausch Health Companies Inc Recent Developments/Updates
    Table 135. Key Raw Materials Lists
    Table 136. Raw Materials Key Suppliers Lists
    Table 137. Dermatomyositis Treatment Distributors List
    Table 138. Dermatomyositis Treatment Customers List
    Table 139. Dermatomyositis Treatment Market Trends
    Table 140. Dermatomyositis Treatment Market Drivers
    Table 141. Dermatomyositis Treatment Market Challenges
    Table 142. Dermatomyositis Treatment Market Restraints
    Table 143. Research Programs/Design for This Report
    Table 144. Key Data Information from Secondary Sources
    Table 145. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Dermatomyositis Treatment
    Figure 2. Global Dermatomyositis Treatment Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Dermatomyositis Treatment Market Share by Type in 2023 & 2030
    Figure 4. Immunosuppressants Product Picture
    Figure 5. Glucocorticoids Product Picture
    Figure 6. Global Dermatomyositis Treatment Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 7. Global Dermatomyositis Treatment Market Share by Application in 2023 & 2030
    Figure 8. Hospital
    Figure 9. Specialty Clinic
    Figure 10. Other
    Figure 11. Global Dermatomyositis Treatment Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 12. Global Dermatomyositis Treatment Market Size (2019-2030) & (US$ Million)
    Figure 13. Global Dermatomyositis Treatment Sales (2019-2030) & (K Units)
    Figure 14. Global Dermatomyositis Treatment Average Price (US$/Unit) & (2019-2030)
    Figure 15. Dermatomyositis Treatment Report Years Considered
    Figure 16. Dermatomyositis Treatment Sales Share by Manufacturers in 2023
    Figure 17. Global Dermatomyositis Treatment Revenue Share by Manufacturers in 2023
    Figure 18. The Global 5 and 10 Largest Dermatomyositis Treatment Players: Market Share by Revenue in 2023
    Figure 19. Dermatomyositis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 20. Global Dermatomyositis Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 21. North America Dermatomyositis Treatment Sales Market Share by Country (2019-2030)
    Figure 22. North America Dermatomyositis Treatment Revenue Market Share by Country (2019-2030)
    Figure 23. United States Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 24. Canada Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 25. Europe Dermatomyositis Treatment Sales Market Share by Country (2019-2030)
    Figure 26. Europe Dermatomyositis Treatment Revenue Market Share by Country (2019-2030)
    Figure 27. Germany Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 28. France Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 29. U.K. Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. Italy Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. Russia Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Asia Pacific Dermatomyositis Treatment Sales Market Share by Region (2019-2030)
    Figure 33. Asia Pacific Dermatomyositis Treatment Revenue Market Share by Region (2019-2030)
    Figure 34. China Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 35. Japan Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 36. South Korea Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. India Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. Australia Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. China Taiwan Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Southeast Asia Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. Latin America Dermatomyositis Treatment Sales Market Share by Country (2019-2030)
    Figure 42. Latin America Dermatomyositis Treatment Revenue Market Share by Country (2019-2030)
    Figure 43. Mexico Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Brazil Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Argentina Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 46. Middle East & Africa Dermatomyositis Treatment Sales Market Share by Country (2019-2030)
    Figure 47. Middle East & Africa Dermatomyositis Treatment Revenue Market Share by Country (2019-2030)
    Figure 48. Turkey Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Saudi Arabia Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 50. UAE Dermatomyositis Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 51. Global Sales Market Share of Dermatomyositis Treatment by Type (2019-2030)
    Figure 52. Global Revenue Market Share of Dermatomyositis Treatment by Type (2019-2030)
    Figure 53. Global Dermatomyositis Treatment Price (US$/Unit) by Type (2019-2030)
    Figure 54. Global Sales Market Share of Dermatomyositis Treatment by Application (2019-2030)
    Figure 55. Global Revenue Market Share of Dermatomyositis Treatment by Application (2019-2030)
    Figure 56. Global Dermatomyositis Treatment Price (US$/Unit) by Application (2019-2030)
    Figure 57. Dermatomyositis Treatment Value Chain
    Figure 58. Dermatomyositis Treatment Production Process
    Figure 59. Channels of Distribution (Direct Vs Distribution)
    Figure 60. Distributors Profiles
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Heart Valve Repair Products - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-0F18702
Tue Oct 22 00:00:00 UTC 2024

Add to Cart

Severe Hypertriglyceridemia (SHTG) Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-3Y14261
Mon Oct 21 00:00:00 UTC 2024

Add to Cart

Birch Allergy Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-29C13700
Mon Oct 21 00:00:00 UTC 2024

Add to Cart

Lithotripsy Devices - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-15D7478
Tue Oct 15 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions